City Therapeutics, Inc. (CTY) shareholders
Close on Nov 17, 2026Market cap –P/E –Yield –
Ownership
Who owns City Therapeutics's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kristina Burow Joint filing with ARCH Venture Fund XII, L.P. (25.60%), ARCH Venture Partners XII, L.P. (25.60%) and 4 more | 13,692,507 | 25.60% | 13D (active) | Oct 19, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (14.00%) | 7,025,543 | 14.00% | 13G (passive) | Oct 30, 2026 |
| Raymond Debbane Joint filing with Invus Public Equities, L.P. (8.10%), Invus Public Equities Advisors, LLC (8.10%) and 2 more | 4,342,866 | 8.10% | 13G (passive) | Oct 16, 2026 |
| Halvorsen Ole Andreas Joint filing with Viking Global Investors LP (7.00%), Viking Global Opportunities Parent GP LLC (7.00%) and 1 more | 3,727,005 | 7.00% | 13G (passive) | Oct 19, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Andrew C. Orth | President & CEO, Director | 1,063,154 | Oct 19, 2026 |
| Tracy Zimmermann | Chief Scientific Officer | – | Oct 15, 2026 |
| Keith Regnante | Chief Financial Officer | – | Oct 15, 2026 |
| Baisong Mei | Chief Medical Officer | 228,743 | Oct 15, 2026 |
| Sebastian Trousil | Chief Operating Officer | 534,511 | Oct 15, 2026 |
| Barry E. Greene | Director | – | Oct 19, 2026 |
| John Maraganore | Director | 2,107,706 | Oct 19, 2026 |
| Sara Nochur | Director | – | Oct 19, 2026 |
| Robert Nelsen | Director, 10% owner | 13,692,507 | Oct 19, 2026 |
| Ron M. Philip | Director | – | Oct 19, 2026 |
| Keith Crandell | 10% owner | – | Oct 19, 2026 |
| Kristina Burow | 10% owner | – | Oct 19, 2026 |
| Steven Gillis | 10% owner | – | Oct 19, 2026 |
| ARCH Venture Fund XII, L.P. | 10% owner | – | Oct 19, 2026 |
| ARCH Venture Partners XII, L.P. | 10% owner | – | Oct 19, 2026 |
| ARCH Venture Partners XII, LLC | 10% owner | 13,692,507 | Oct 19, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC 10% owner | Oct 19, 2026 | Buy | +170,000 | $18.00 | $3.06M | 13,692,507 |
| ARCH Venture Partners XII, LLC 10% owner | Oct 19, 2026 | Conversion | +2,027,006 | – | – | 13,522,507 |
| ARCH Venture Partners XII, LLC 10% owner | Oct 19, 2026 | Conversion | +5,482,309 | – | – | 11,495,501 |
| ARCH Venture Partners XII, LLC 10% owner | Oct 19, 2026 | Conversion | +3,294,900 | – | – | 6,013,192 |
| Robert Nelsen Director, 10% owner | Oct 19, 2026 | Buy | +170,000 | $18.00 | $3.06M | 13,692,507 |
| Robert Nelsen Director, 10% owner | Oct 19, 2026 | Conversion | +2,027,006 | – | – | 13,522,507 |
| Robert Nelsen Director, 10% owner | Oct 19, 2026 | Conversion | +5,482,309 | – | – | 11,495,501 |
| Robert Nelsen Director, 10% owner | Oct 19, 2026 | Conversion | +3,294,900 | – | – | 6,013,192 |
| John Maraganore Director | Oct 19, 2026 | Conversion | +610,759 | – | – | 1,470,692 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of City Therapeutics's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
Congress trades
1 trade in City Therapeutics reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Raúl M. Grijalva AZ03 | Sold | Jan 15, 2014 | $1K–15K | Feb 5, 2014 |
See a number that looks wrong?